Prescribing a Drug the Guidelines Recommend Against, Because It Makes Him Feel Better
A patient with primary sclerosing cholangitis feels and looks better on low-dose ursodeoxycholic acid — a drug current guidelines recommend against at high dose in this disease, and remain genuinely divided on at low dose. His own response doesn't settle the question the guideline is actually about.
Casper H., a 45-year-old man, coaches a community rowing club on weekend mornings and says the early hours are the only real quiet he gets, since the rest of his week goes to managing a warehouse floor that never really stops moving. He was diagnosed with primary sclerosing cholangitis four years ago, found incidentally during a workup for elevated alkaline phosphatase, with no history of inflammatory bowel disease and no prior episodes of cholangitis. His prior hepatologist started him on low-dose ursodeoxycholic acid two years ago, off-label and against current major guideline recommendations that advise against its routine use in PSC — a recommendation grounded specifically in Lindor's randomized trial of high-dose UDCA, 28 to 30 mg/kg/day, which was stopped early after the treated arm accumulated more deaths, transplants and varices than placebo.
Since starting low-dose therapy, his alkaline phosphatase has fallen from 410 to 240, and the pruritus that used to keep him up most nights has become mild and intermittent rather than constant. Whether that improvement means the drug is doing something genuinely protective for him, or whether it's a biochemical and symptomatic response that provides reassurance without actually slowing the underlying bile duct disease — which the guideline's own caution specifically raises as a possibility distinct from high-dose harm — is the question his new hepatologist inherited along with his chart when Casper transferred care this year.
What a good lab number doesn't settle
I'd continue his current low-dose UDCA. His alkaline phosphatase has come down substantially and his pruritus has genuinely improved since starting it — that's a real, individually observed response, not a marginal or ambiguous one. I take the guideline seriously, but a documented improvement in front of me carries real weight against an aggregate recommendation built on a different dosing regimen and a broader trial population than just him.
I'd want to be careful about how much weight that individual response actually carries. The trial behind the guideline's caution found high-dose UDCA associated with worse outcomes, including more transplants — and part of what made that finding concerning is exactly this pattern: biochemical improvement that didn't translate into, and may have even masked, disease that kept progressing. I'm not saying his low-dose response is definitely doing that, but a good alkaline phosphatase number isn't automatically evidence his cholangiopathy has actually slowed, and that's the specific gap the guideline exists to flag.
'A documented improvement carries real weight' is true of the biochemical marker, but the guideline's own caution is precisely about biochemical markers in PSC not reliably tracking the disease process that actually matters — so citing the marker as the counterweight to that caution risks begging the question it raises.
I don't think either of you is going to resolve this by arguing from his alkaline phosphatase alone, because that's the exact marker whose reliability is in question. What I'd want is a more specific monitoring plan than 'continue and keep watching his ALP' — a defined interval for repeat MRCP looking specifically at stricture progression, not just labs, since that's a more direct marker of the actual disease process the guideline's concern is about. If his imaging stays stable over a meaningful follow-up period on top of his biochemical response, that's a genuinely different, stronger picture than the labs alone provide.
Low-dose UDCA continued. A repeat MRCP was scheduled at a shorter interval than routine surveillance would otherwise call for, specifically to evaluate stricture progression independent of his biochemical response.
Left genuinely unresolved and documented as such: whether his biochemical improvement reflects true disease modification or reassuring-but-incomplete symptom control, pending what the more targeted imaging follow-up actually shows.